AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19527189 — intervention group
Group type: EXPERIMENTAL
Intervention: Local oestrogen therapy
Number of subjects: 0
Study 19527189 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs enhancing nitric oxide or vasoactive intestinal polypeptide
Number of subjects: 0
Study 19527189 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase inhibitors
Number of subjects: 0
Study 19527189 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of dihydroepiandrosterone
Number of subjects: 0
Study 17241419 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BT‐A) 50 U
Number of subjects: 51
Study 17241419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 14722892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 800/200 mg once daily
Number of subjects: 38
Study 14722892 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg twice daily
Number of subjects: 38
Study 11139311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paclitaxel (120 mg/m²) with GF120918 (1000 mg)
Number of subjects: 6
Study 11139311 — intervention group
Group type: COMPARATOR
Intervention: Oral paclitaxel (120 mg/m²) with CsA (previous study)
Number of subjects: 6
Study 11139311 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paclitaxel (175 mg/m²)
Number of subjects: 6
Study 9596394 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 100 BTA U into the tibialis posterior muscle, followed by ankle-foot taping (group B)
Number of subjects: 18
Study 9596394 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 190 to 320 BTA U into several calf muscles (group A)
Number of subjects: 18
Study 7889428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate Aqueous Nasal Spray (FPANS) 200 micrograms once daily
Number of subjects: 214
Study 7889428 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine tablets (60 mg) twice daily
Number of subjects: 214
Study 7889428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 3498406 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg . kg‐1 propofol
Number of subjects: 60
Study 3498406 — intervention group
Group type: COMPARATOR
Intervention: 2 mg . kg‐1 methohexitone
Number of subjects: 60
Study 3498406 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg . kg‐1 with fentanyl 1.5 micrograms . kg‐1
Number of subjects: 60
Study 3498406 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 micrograms . kg‐1 with vecuronium 0.1 mg . kg‐1
Number of subjects: 60
Study 3498406 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone 2 mg . kg‐1
Number of subjects: 60
Study 3498406 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and methohexitone
Number of subjects: 60
Study 29518468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrients highly related to nutritional quality highlighted using a front‐of‐package (FOP) label
Number of subjects: 0
Study 29518468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrients unrelated to nutritional quality highlighted using a front‐of‐package (FOP) label
Number of subjects: 0
Study 29518468 — intervention group
Group type: COMPARATOR
Intervention: No nutritional information highlighted
Number of subjects: 0
Study 28651642 — intervention group
Group type: EXPERIMENTAL
Intervention: si guan xue plus commonly used acupoints arm (n=14)
Number of subjects: 42
Study 28651642 — intervention group
Group type: EXPERIMENTAL
Intervention: si guan xue arm (n=14)
Number of subjects: 42
Study 28651642 — intervention group
Group type: COMPARATOR
Intervention: commonly used acupoints arm (n=14)
Number of subjects: 42
Study 26163088 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 754
Study 23769959 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (SECPT)
Number of subjects: 36
Study 23769959 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study 21688915 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 66
Study 21688915 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 66
Study 19549706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off)
Number of subjects: 304
Study 19549706 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (9 million units s.c. injection three times/week)
Number of subjects: 304
Study 16512083 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit, systematic reading intervention in Spanish for treatment group (daily for 50 min)
Number of subjects: 69
Study 12649125 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus recombinant surfactant protein C surfactant (Venticute) given four times over 24 hours
Number of subjects: 0
Study 12649125 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 11460286 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Delton)
Number of subjects: 140
Study 11460286 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (Fuji III)
Number of subjects: 140
Study 11460286 — intervention group
Group type: COMPARATOR
Intervention: Dentist with chairside assistance (both sealants)
Number of subjects: 140
Study 8671224 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen for 12 days
Number of subjects: 20
Study 8671224 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen and Crinone (vaginal progesterone) for another 12 days
Number of subjects: 20
Study 1418078 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 19
Study 1418078 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid plus rifampicin (RMP)
Number of subjects: 19
Study 1418078 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study 6549147 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide, Methotrexate, and Fluorouracil)
Number of subjects: 49
Study 6549147 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide, Methotrexate, and Fluorouracil) plus tamoxifen
Number of subjects: 49
Study 31609787 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 30 U
Number of subjects: 255
Study 31609787 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 50 U
Number of subjects: 255
Study 31609787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 30883859 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring frequency decreased at a CD4 threshold of 350 cells/μl
Number of subjects: 0
Study 30883859 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment switched at an HIV-RNA threshold of 1000 copies/ml
Number of subjects: 0
Study 30883859 — intervention group
Group type: EXPERIMENTAL
Intervention: No direct effect assumption
Number of subjects: 0
Study 29278315 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone
Number of subjects: 0
Study 29278315 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26772449 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and zinc combined supplementation
Number of subjects: 0
Study 26772449 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 26772449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26772449 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily zinc supplement
Number of subjects: 0
Study 26772449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin A-zinc supplement
Number of subjects: 0
Study 26772449 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A every 2 months
Number of subjects: 0
Study 23978948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 μg/ml
Number of subjects: 60
Study 23978948 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.1%
Number of subjects: 60
Study 23978948 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 60
Study 22882515 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective resection of dorsal nerve (SRDN)
Number of subjects: 101
Study 22882515 — intervention group
Group type: COMPARATOR
Intervention: Circumcision only (Control)
Number of subjects: 101
Study 19225354 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004% eye drops
Number of subjects: 37
Study 19225354 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal eyes)
Number of subjects: 37
Study 17472485 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/1.2 g NT-GA combination
Number of subjects: 105
Study 17472485 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/2.4 g NT-GA combination
Number of subjects: 105
Study 17472485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15183553 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-learning programme (educational package for the GP and a patient information leaflet)
Number of subjects: 151
Study 15183553 — intervention group
Group type: COMPARATOR
Intervention: Written guidelines on LUTS mailed to the GP (Control)
Number of subjects: 151
Study 12575373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone inhalation combined with Jinacon (JNC)
Number of subjects: 72
Study 12575373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone inhalation alone
Number of subjects: 72
Study 12575373 — intervention group
Group type: EXPERIMENTAL
Intervention: JNC alone
Number of subjects: 72
Study 9649143 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg day(-1)
Number of subjects: 66
Study 9649143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 7843478 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps
Number of subjects: 508
Study 7843478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventouse
Number of subjects: 508
Study 2656777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonazocine mesylate 4 mg
Number of subjects: 150
Study 2656777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonazocine mesylate 8 mg
Number of subjects: 150
Study 2656777 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 10 mg
Number of subjects: 150
Study 2656777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 1080959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic doses of steroids administered early in the shock state (within the first hour) for periods of less than forty-eight hours
Number of subjects: 0
Study 31122129 — intervention group
Group type: EXPERIMENTAL
Intervention: English speakers
Number of subjects: 0
Study 31122129 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish speakers
Number of subjects: 0
Study 31694845 — intervention group
Group type: EXPERIMENTAL
Intervention: VHA-guided management of bleeding
Number of subjects: 1000
Study 28359172 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPARA device
Number of subjects: 37
Study 28359172 — intervention group
Group type: COMPARATOR
Intervention: Control (oral airway only)
Number of subjects: 37
Study 25933111 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/day)
Number of subjects: 364
Study 25933111 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/Gemcitabine (up to six cycles; cisplatin 75 mg/m2 [d1]; gemcitabine 1000 mg/m2 [d1,8])
Number of subjects: 364
Study 25933111 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 364
Study 23714411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mums Step it Up Program
Number of subjects: 126
Study 23714411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer only
Number of subjects: 126
Study 23714411 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study 21742485 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 250mg/m² q3w (first cycle) increased to 350mg/m² depending on toxicity
Number of subjects: 40
Study 21742485 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 40
Study 21742485 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 40
Study 19421851 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent monetary incentives ($1, $2, $5, mood magnet)
Number of subjects: 500
Study 19421851 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 500
Study 16009445 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day for 12 weeks
Number of subjects: 40
Study 16009445 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day followed by Fenofibrate 200 mg/day for an additional 12 weeks
Number of subjects: 40
Study 14959471 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard drugs plus bicycle exercise (group 1)
Number of subjects: 100
Study 14959471 — intervention group
Group type: COMPARATOR
Intervention: Standard drugs only (group 2)
Number of subjects: 100
Study 10849577 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise at 60-75% of maximum aerobic capacity, 3 days per week, 30 min per session
Number of subjects: 0
Study 10849577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise using brisk walking for two, 15 min sessions, 5 days per week
Number of subjects: 0
Study 9322328 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 323
Study 9322328 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy treatment
Number of subjects: 323
Study 8442964 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ondansetron (two 8 mg doses 8 hours apart)
Number of subjects: 207
Study 8442964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 3536525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary talc
Number of subjects: 41
Study 3536525 — intervention group
Group type: COMPARATOR
Intervention: Intracavitary tetracycline
Number of subjects: 41
Study 30782675 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical skin camouflage (MSC) intervention for 6 weeks
Number of subjects: 40
Study 30782675 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (no MSC during study period)
Number of subjects: 40
Study 30782675 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews and focus groups with prison staff and women prisoners
Number of subjects: 40
Study 30005647 — intervention group
Group type: EXPERIMENTAL
Intervention: Road safety bus stickers in minibuses
Number of subjects: 2410
Study 30005647 — intervention group
Group type: EXPERIMENTAL
Intervention: Road safety bus stickers in big buses
Number of subjects: 2410
Study 26947212 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care (family physician notification and follow-up)
Number of subjects: 227
Study 26947212 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care
Number of subjects: 227
Study 25526794 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital multiuse breathalyser
Number of subjects: 208
Study 25526794 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use breathalyser 1
Number of subjects: 208
Study 25526794 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use breathalyser 2
Number of subjects: 208
Study 25526794 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported alcohol consumption threshold of 5 UK units or fewer
Number of subjects: 208
Study 22101394 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (125 mg)
Number of subjects: 32
Study 22101394 — intervention group
Group type: COMPARATOR
Intervention: Exposure/Response Prevention (Exp/RP)
Number of subjects: 32
Study 20850097 — intervention group
Group type: EXPERIMENTAL
Intervention: SeptRx PFO closure device
Number of subjects: 13
Study 20850097 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg and Clopidogrel 75 mg for 6 months
Number of subjects: 13
Study 18046991 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) questionnaire for patients with type II diabetes
Number of subjects: 126
Study 12600252 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid release with Air Viva 2 circuit
Number of subjects: 15
Study 12600252 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid release with Mapleson-C circuit
Number of subjects: 15
Study 12600252 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid release with Mapleson-F circuit
Number of subjects: 15
Study 12600252 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger volume delivery
Number of subjects: 15
Study 12600252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower target volume with Mapleson circuits and rapid release
Number of subjects: 15
Study 12600252 — intervention group
Group type: COMPARATOR
Intervention: Air Viva 2 circuit without rapid release
Number of subjects: 15
Study 12600252 — intervention group
Group type: COMPARATOR
Intervention: Mapleson-C circuit without rapid release
Number of subjects: 15
Study 12600252 — intervention group
Group type: COMPARATOR
Intervention: Mapleson-F circuit without rapid release
Number of subjects: 15
Study 10705425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 130
Study 10705425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 130
Study 10705425 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine around the sheath site
Number of subjects: 130
Study 10705425 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 130
Study 9373656 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days treatment with Quinimax® (10 mg/kg twice daily)
Number of subjects: 145
Study 9373656 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days treatment with Quinimax® (10 mg/kg twice daily)
Number of subjects: 145
Study 9373656 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days treatment with Quinimax® (10 mg/kg twice daily)
Number of subjects: 145
Study 7839883 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study 7839883 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Number of subjects: 0
Study 7839883 — intervention group
Group type: COMPARATOR
Intervention: Control (multivite group)
Number of subjects: 0
Study 3755702 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meniscectomy
Number of subjects: 200
Study 3755702 — intervention group
Group type: COMPARATOR
Intervention: Total meniscectomy
Number of subjects: 200
Study 31978060 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular xenomonitoring (MX) survey
Number of subjects: 9804
Study 31978060 — intervention group
Group type: COMPARATOR
Intervention: Transmission Assessment Survey (TAS)
Number of subjects: 9804
Study 31978060 — intervention group
Group type: COMPARATOR
Intervention: Microfilaria (Mf) survey
Number of subjects: 9804
Study 31978060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost comparison of TAS and MX
Number of subjects: 9804
Study 26615475 — intervention group
Group type: EXPERIMENTAL
Intervention: Video (VI) group
Number of subjects: 40
Study 26615475 — intervention group
Group type: EXPERIMENTAL
Intervention: External Focus (EF) group
Number of subjects: 40
Study 26615475 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Focus (IF) group
Number of subjects: 40
Study 26615475 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL) group
Number of subjects: 40
Study 24189454 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 24189454 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 23050526 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy implementation (discontinuation of additional payments for preventable infections)
Number of subjects: 398
Study 20033629 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention
Number of subjects: 101
Study 20033629 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 101
Study 20033629 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 101
Study 18511530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroid (1 mL, 40 mg methylprednisolone acetate) followed by a 12‐week comprehensive home exercise programme
Number of subjects: 80
Study 18511530 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular serum physiologic (1 mL solution of 0.9% sodium chloride) followed by a 12‐week comprehensive home exercise programme
Number of subjects: 80
Study 15818711 — intervention group
Group type: EXPERIMENTAL
Intervention: dsDNA‐based bioconjugate (abetimus sodium; LJP 394)
Number of subjects: 487
Study 15818711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 9890616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual energy x-ray absorptiometry (DXA)
Number of subjects: 45
Study 9049962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (CCG-1800 series, 1989-1994)
Number of subjects: 730
Study 9049962 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity chemotherapy (CCG-100 series, 1983-1989)
Number of subjects: 730
Study 1802206 — intervention group
Group type: EXPERIMENTAL
Intervention: BHGH (0.25 IU.kg-1.day-1) with surgery and TPN
Number of subjects: 30
Study 1802206 — intervention group
Group type: EXPERIMENTAL
Intervention: BHGH (0.25 IU.kg-1.day-1) with TPN
Number of subjects: 30
Study 1802206 — intervention group
Group type: COMPARATOR
Intervention: Control group (TPN only)
Number of subjects: 30
Study 1802206 — intervention group
Group type: EXPERIMENTAL
Intervention: BHGH (0.25 IU.kg-1.day-1)
Number of subjects: 30
Study 6129091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafenolol (5 mg)
Number of subjects: 7
Study 6129091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafenolol (7.5 mg)
Number of subjects: 7
Study 6129091 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg)
Number of subjects: 7
Study 6129091 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study 6129091 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (inhaled in increasing doses)
Number of subjects: 7
Study 30871431 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative methods used in RCTs
Number of subjects: 0